Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. Wegovy is a ...

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.

The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control ...